Dreams for type 1 diabetes: Shutting off autoimmunity and stimulating β-cell regeneration

Endocrinology

Volumn 151, Issue 7, 2010, Pages 2971-2973

  Weir, Gordon C ^a   Bonner Weir, Susan ^a  

^a HARVARD MEDICAL SCHOOL   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

AUTOIMMUNITY; CELL REGENERATION; HUMAN; INSULIN DEPENDENT DIABETES MELLITUS; NONHUMAN; PANCREAS ISLET BETA CELL; PRIORITY JOURNAL; SHORT SURVEY; ANIMAL; BLOOD; CYTOLOGY; DRUG EFFECT; FEMALE; IMMUNOLOGY; MOUSE; NONOBESE DIABETIC MOUSE; NOTE; REGULATORY T LYMPHOCYTE;

1 (((2 ((5 CYANOPYRIDIN 2 YL)AMINO)ETHYL)AMINO)ACETYL) 2 CYANO (S) PYRROLIDINE; 1-(((2-((5-CYANOPYRIDIN-2-YL)AMINO)ETHYL)AMINO)ACETYL)-2-CYANO-(S)-PYRROLIDINE; DIPEPTIDYL PEPTIDASE IV INHIBITOR; NITRILE; PYRROLIDINE DERIVATIVE;

ANIMALS; DIABETES MELLITUS, TYPE 1; DIPEPTIDYL-PEPTIDASE IV INHIBITORS; FEMALE; INSULIN-SECRETING CELLS; MICE; MICE, INBRED NOD; NITRILES; PYRROLIDINES; T-LYMPHOCYTES, REGULATORY;

EID: 77954601358     PISSN: 00137227     EISSN: 00137227     Source Type: Journal    
DOI: 10.1210/en.2010-0538     Document Type: Short Survey

References (22)

1. Suarez-Pinzon WL, Cembrowski GS, Rabinovitch A 2009 Combination therapy with a dipeptidyl peptidase-4 inhibitor and a proton pump inhibitor restores normoglycaemia in non-obese diabetic mice. Diabetologia 52:1680-1682
2. Tian L, Gao J, Hao J, Zhang Y, Yi H, O'Brien TD, Sorenson R, Luo J, Guo Z 2010 Reversal of new-onset diabetes through modulating inflammation and stimulating β-cell replication in nonobese diabetic mice by a dipeptidyl peptidase IV inhibitor. Endocrinology 151: 000-0000
3. Drucker DJ 2006 The biology of incretin hormones. Cell Metab 3:153-165
4. Morimoto C, Schlossman SF 1998 The structure and function of CD26 in the T-cell immune response. Immunol Rev 161:55-70 (Pubitemid 28119018)
5. Steinbrecher A, Reinhold D, Quigley L, Gado A, Tresser N, Izikson L, Born I, Faust J, Neubert K, Martin R, Ansorge S, Brocke S 2001 Targeting dipeptidyl peptidase IV (CD26) suppresses autoimmune encephalomyelitis and up-regulates TGF-β1 secretion in vivo. J Immunol 166:2041-2048 (Pubitemid 32114693)
6. Suarez-Pinzon WL, Power RF, Yan Y, Wasserfall C, Atkinson M, Rabinovitch A 2008 Combination therapy with glucagon-like peptide-1 and gastrin restores normoglycemia in diabetic NOD mice. Diabetes 57:3281-3288
7. Li Y, Hansotia T, Yusta B, Ris F, Halban PA, Drucker DJ 2003 Glucagon-like peptide-1 receptor signaling modulates β cell apoptosis. J Biol Chem 278:471-478 (Pubitemid 36043598)
8. Park S, Dong X, Fisher TL, Dunn S, Omer AK, Weir G, White MF 2006 Exendin-4 uses Irs2 signaling to mediate pancreatic β cell growth and function. J Biol Chem 281:1159-1168
9. Suarez-Pinzon WL, Lakey JR, Brand SJ, Rabinovitch A 2005 Combination therapy with epidermal growth factor and gastrin induces neogenesis of human islet β-cells from pancreatic duct cells and an increase in functional β-cell mass. J Clin Endocrinol Metab 90:3401-3409 (Pubitemid 41014304)
10. Thorel F, Népote V, Avril I, Kohno K, Desgraz R, Chera S, Herrera PL 2010 Conversion of adult pancreatic α-cells to β-cells after extreme β-cell loss. Nature 464:1149-1154
11. Koulmanda M, Bhasin M, Hoffman L, Fan Z, Qipo A, Shi H, Bonner-Weir S, Putheti P, Degauque N, Libermann TA, Auchincloss Jr H, Flier JS, Strom TB 2008 Curative and β cell regenerative effects of α1-antitrypsin treatment in autoimmune diabetic NOD mice. Proc Natl Acad Sci USA 105:16242-16247
12. Sherry NA, Kushner JA, Glandt M, Kitamura T, Brillantes AM, Herold KC 2006 Effects of autoimmunity and immune therapy on β-cell turnover in type 1 diabetes. Diabetes 55:3238-3245 (Pubitemid 44923579)
13. Koulmanda M, Budo E, Bonner-Weir S, Qipo A, Putheti P, Degauque N, Shi H, Fan Z, Flier JS, Auchincloss Jr H, Zheng XX, Strom TB 2007 Modification of adverse inflammation is required to cure new-onset type 1 diabetic hosts. Proc Natl Acad Sci USA 104:13074-13079 (Pubitemid 351737595)
14. Weir GC, Bonner-Weir S 2004 Five stages of evolving β-cell dysfunction during progression to diabetes. Diabetes 53(Suppl 3):S16-S21 (Pubitemid 39564517)
15. Chatenoud L, Primo J, Bach JF 1997 CD3 antibody-induced dominant self tolerance in overtly diabetic NOD mice. J Immunol 158: 2947-2954 (Pubitemid 127470558)
16. Chatenoud L, Thervet E, Primo J, Bach JF 1994 Anti-CD3 antibody induces long-term remission of overt autoimmunity in nonobese diabetic mice. Proc Natl Acad Sci USA 91:123-127 (Pubitemid 24018655)
17. Tian B, Hao J, Zhang Y, Tian L, Yi H, O'Brien TD, Sutherland DE, Hering BJ, Guo Z 2009 Upregulating CD4+CD25+ FOXP3+ regulatory T cells in pancreatic lymph nodes in diabetic NOD mice by adjuvant immunotherapy. Transplantation 87: 198-206
18. Xu G, Stoffers DA, Habener JF, Bonner-Weir S 1999 Exendin-4 stimulates both β-cell replication and neogenesis, resulting in increased β-cell mass and improved glucose tolerance in diabetic rats. Diabetes 48:2270-2276 (Pubitemid 30395416)
19. Herold KC, Gitelman SE, Masharani U, Hagopian W, Bisikirska B, Donaldson D, Rother K, Diamond B, Harlan DM, Bluestone JA 2005 A single course of anti-CD3 monoclonal antibody hOKT3γ1 (Ala-Ala) results in improvement in C-peptide responses and clinical parameters for at least 2 years after onset of type 1 diabetes. Diabetes 54:1763-1769 (Pubitemid 40770766)
20. Pescovitz MD, Greenbaum CJ, Krause-Steinrauf H, Becker DJ, Gitelman SE, Goland R, Gottlieb PA, Marks JB, McGee PF, Moran AM, Raskin P, Rodriguez H, Schatz DA, Wherrett D, Wilson DM, Lachin JM, Skyler JS; Type 1 Diabetes TrialNet Anti CDSG 2009 Rituximab, B-lymphocyte depletion, and preservation of β-cell function. N Engl J Med 361:2143-2152
21. Couri CE, Oliveira MC, Stracieri AB, Moraes DA, Pieroni F, Barros GM, Madeira MI, Malmegrim KC, Foss-Freitas MC, Simões BP, Martinez EZ, Foss MC, Burt RK, Voltarelli JC 2009 C-peptide levels and insulin independence following autologous nonmyeloablative hematopoietic stem cell transplantation in newly diagnosed type 1 diabetes mellitus. JAMA 301:1573-1579
22. Halban PA, German MS, Kahn SE, Weir GC 2010 Current status of islet cell replacement and regeneration therapy. J Clin Endocrinol Metab 95:1034-1043